Revolution Medicines, Inc. (RVMD) Current Ratio
- Current ratio · latest quarter: Value 11.38×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 11.38× | Current assets / current liabilities. $4.03B ÷ $354.06M ≈ 11.38× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 4.03B USD | Assets, Current |
| Current obligations | 354.06M USD | Liabilities, Current |
| Cash and equivalents | 815.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 3.12B USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 88.42M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.03B | $354.06M | $815.43M | $3.12B | (m) | (m) | $88.42M | (m) | 11.38× |
| 2026-03-31 | $1.97B | $289.60M | $440.94M | $1.47B | (m) | (m) | $80.54M | (m) | 6.80× |
| 2025-12-31 | $2.08B | $290.42M | $383.75M | $1.64B | (m) | (m) | $64.62M | (m) | 7.14× |
| 2025-09-30 | $1.98B | $245.62M | $217.44M | $1.71B | (m) | (m) | $74.85M | (m) | 8.05× |
| 2025-06-30 | $2.18B | $184.53M | $402.44M | $1.73B | (m) | (m) | $56.76M | (m) | 11.79× |
| 2025-03-31 | $2.13B | $158.60M | $333.55M | $1.77B | (m) | (m) | $47.51M | (m) | 13.46× |
| 2024-12-31 | $2.33B | $163.91M | $543.06M | $1.75B | (m) | (m) | $54.43M | (m) | 14.20× |
| 2024-09-30 | $1.58B | $110.86M | $201.26M | $1.35B | (m) | (m) | $24.46M | (m) | 14.24× |
| 2024-06-30 | $1.62B | $105.33M | $275.71M | $1.32B | (m) | (m) | $29.32M | (m) | 15.42× |
| 2024-03-31 | $1.73B | $93.72M | $288.43M | $1.42B | (m) | (m) | $32.38M | (m) | 18.45× |
| 2023-12-31 | $1.88B | $143.85M | $696.15M | $1.16B | (m) | (m) | $61.79M | (m) | 13.06× |
| 2023-09-30 | $824.47M | $85.54M | $358.40M | $454.80M | (m) | (m) | $29.63M | (m) | 9.64× |
| 2023-06-30 | $922.09M | $78.06M | $380.33M | $529.16M | (m) | (m) | $29.78M | (m) | 11.81× |
| 2023-03-31 | $922.75M | $54.63M | $427.22M | $482.58M | (m) | (m) | $19.91M | (m) | 16.89× |
| 2022-12-31 | $660.18M | $61.98M | $161.41M | $483.53M | (m) | (m) | $21.31M | (m) | 10.65× |
| 2022-09-30 | $675.11M | $73.27M | $178.94M | $476.07M | (m) | (m) | $24.38M | (m) | 9.21× |
| 2022-06-30 | $483.05M | $63.54M | $105.78M | $355.65M | (m) | (m) | $14.07M | (m) | 7.60× |
| 2022-03-31 | $534.34M | $57.46M | $97.67M | $421.09M | (m) | (m) | $14.17M | (m) | 9.30× |
| 2021-12-31 | $589.77M | $60.35M | $108.50M | $468.56M | (m) | (m) | $14.06M | (m) | 9.77× |
| 2021-09-30 | $623.54M | $51.89M | $129.15M | $479.50M | (m) | (m) | $10.49M | (m) | 12.02× |
| 2021-06-30 | $661.01M | $45.80M | $195.60M | $450.72M | (m) | (m) | $10.44M | (m) | 14.43× |
| 2021-03-31 | $697.40M | $43.76M | $351.60M | $330.00M | (m) | (m) | $9.65M | (m) | 15.94× |
| 2020-12-31 | $454.12M | $47.18M | $104.27M | $336.47M | (m) | (m) | $12.61M | (m) | 9.63× |
| 2020-09-30 | $482.90M | $42.38M | $64.87M | $401.27M | (m) | (m) | $6.66M | (m) | 11.39× |
| 2020-06-30 | $340.38M | $43.74M | $23.98M | $301.47M | (m) | (m) | $10.17M | (m) | 7.78× |
| 2020-03-31 | $362.09M | $41.51M | $182.67M | $165.28M | (m) | (m) | $7.88M | (m) | 8.72× |
| 2019-12-31 | $133.98M | $43.05M | $16.66M | $106.10M | (m) | (m) | $11.40M | (m) | 3.11× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |